Do analysts rate BMGL or BGLC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, BMGL or BGLC?

BioNexus Gene Lab has lower revenue, but higher earnings than Basel Medical Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Basel Medical Group $8.90M 1.01 -$9.50M N/A N/A BioNexus Gene Lab $7.43M 0.47 -$2.98M -$1.48 N/A

Do analysts prefer BGLC or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor BGLC or MGRX?

In the previous week, Mangoceuticals had 7 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 8 mentions for Mangoceuticals and 1 mentions for BioNexus Gene Lab. Mangoceuticals' average media sentiment score of 0.51 beat BioNexus Gene Lab's score of 0.00 indicating that Mangoceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNexus Gene Lab 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mangoceuticals 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BRTX or BGLC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend ACON or BGLC?

Aclarion currently has a consensus price target of $7.50, indicating a potential upside of 217.80%. Given Aclarion's stronger consensus rating and higher probable upside, analysts clearly believe Aclarion is more favorable than BioNexus Gene Lab. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer ACON or BGLC?

In the previous week, Aclarion had 1 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 2 mentions for Aclarion and 1 mentions for BioNexus Gene Lab. Aclarion's average media sentiment score of 0.42 beat BioNexus Gene Lab's score of 0.00 indicating that Aclarion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclarion 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioNexus Gene Lab 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend NIVF or BGLC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewGenIvf Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, NIVF or BGLC?

NewGenIvf Group has higher earnings, but lower revenue than BioNexus Gene Lab. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NewGenIvf Group $4.73M 0.47 $9.88M N/A N/A BioNexus Gene Lab $7.43M 0.47 -$2.98M -$1.48 N/A

Does the media prefer NIVF or BGLC?

In the previous week, NewGenIvf Group had 3 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 4 mentions for NewGenIvf Group and 1 mentions for BioNexus Gene Lab. NewGenIvf Group's average media sentiment score of 0.43 beat BioNexus Gene Lab's score of 0.00 indicating that NewGenIvf Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewGenIvf Group 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BioNexus Gene Lab 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

BioNexus Gene Lab (BGLC) Competitors

$1.43 +0.11 (+8.33%)

Closing price 04:00 PM Eastern

Extended Trading

$1.45 +0.02 (+1.40%)

As of 07:04 PM Eastern

Compare

BGLC vs. BMGL, MGRX, BRTX, ACON, and NIVF

Should you buy BioNexus Gene Lab stock or one of its competitors? MarketBeat compares BioNexus Gene Lab with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioNexus Gene Lab include Basel Medical Group (BMGL), Mangoceuticals (MGRX), Biorestorative Therapies (BRTX), Aclarion (ACON), and NewGenIvf Group (NIVF).

How does BioNexus Gene Lab compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and BioNexus Gene Lab (NASDAQ:BGLC) are related small-cap companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

BioNexus Gene Lab has lower revenue, but higher earnings than Basel Medical Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$8.90M	1.01	-$9.50M	N/A	N/A
BioNexus Gene Lab	$7.43M	0.47	-$2.98M	-$1.48	N/A

Basel Medical Group has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -54.70%. Basel Medical Group's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%

Basel Medical Group has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, BioNexus Gene Lab has a beta of 4.17, meaning that its stock price is 317% more volatile than the broader market.

In the previous week, BioNexus Gene Lab had 1 more articles in the media than Basel Medical Group. MarketBeat recorded 1 mentions for BioNexus Gene Lab and 0 mentions for Basel Medical Group. Basel Medical Group's average media sentiment score of 0.00 equaled BioNexus Gene Lab'saverage media sentiment score.

Company	Overall Sentiment
Basel Medical Group	Neutral
BioNexus Gene Lab	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

18.9% of BioNexus Gene Lab shares are owned by institutional investors. 0.1% of BioNexus Gene Lab shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Basel Medical Group and BioNexus Gene Lab tied by winning 5 of the 10 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Mangoceuticals?

BioNexus Gene Lab (NASDAQ:BGLC) and Mangoceuticals (NASDAQ:MGRX) are related small-cap companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

BioNexus Gene Lab has higher revenue and earnings than Mangoceuticals. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$7.43M	0.47	-$2.98M	-$1.48	N/A
Mangoceuticals	$460K	20.01	-$20.64M	-$1.49	N/A

BioNexus Gene Lab has a net margin of -54.70% compared to Mangoceuticals' net margin of -4,639.13%. BioNexus Gene Lab's return on equity of -37.43% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%
Mangoceuticals	-4,639.13%	-112.00%	-104.96%

BioNexus Gene Lab has a beta of 4.17, meaning that its stock price is 317% more volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

18.9% of BioNexus Gene Lab shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 0.1% of BioNexus Gene Lab shares are owned by company insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Mangoceuticals had 7 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 8 mentions for Mangoceuticals and 1 mentions for BioNexus Gene Lab. Mangoceuticals' average media sentiment score of 0.51 beat BioNexus Gene Lab's score of 0.00 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNexus Gene Lab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mangoceuticals	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioNexus Gene Lab beats Mangoceuticals on 7 of the 13 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Biorestorative Therapies?

Biorestorative Therapies (NASDAQ:BRTX) and BioNexus Gene Lab (NASDAQ:BGLC) are related small-cap companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, BioNexus Gene Lab had 1 more articles in the media than Biorestorative Therapies. MarketBeat recorded 1 mentions for BioNexus Gene Lab and 0 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 0.00 equaled BioNexus Gene Lab'saverage media sentiment score.

Company	Overall Sentiment
Biorestorative Therapies	Neutral
BioNexus Gene Lab	Neutral

69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Biorestorative Therapies has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, BioNexus Gene Lab has a beta of 4.17, suggesting that its stock price is 317% more volatile than the broader market.

BioNexus Gene Lab has a net margin of -54.70% compared to Biorestorative Therapies' net margin of -3,088.27%. BioNexus Gene Lab's return on equity of -37.43% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%

BioNexus Gene Lab has higher revenue and earnings than Biorestorative Therapies. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360K	14.01	-$14.24M	-$1.07	N/A
BioNexus Gene Lab	$7.43M	0.47	-$2.98M	-$1.48	N/A

Summary

BioNexus Gene Lab beats Biorestorative Therapies on 7 of the 11 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Aclarion?

Aclarion (NASDAQ:ACON) and BioNexus Gene Lab (NASDAQ:BGLC) are related small-cap companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

BioNexus Gene Lab has higher revenue and earnings than Aclarion. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80K	72.57	-$7.23M	-$9.03	N/A
BioNexus Gene Lab	$7.43M	0.47	-$2.98M	-$1.48	N/A

Aclarion has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, BioNexus Gene Lab has a beta of 4.17, meaning that its stock price is 317% more volatile than the broader market.

7.5% of Aclarion shares are owned by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are owned by institutional investors. 0.0% of Aclarion shares are owned by company insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

BioNexus Gene Lab has a net margin of -54.70% compared to Aclarion's net margin of -10,320.51%. BioNexus Gene Lab's return on equity of -37.43% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,320.51%	-54.41%	-51.71%
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%

Aclarion currently has a consensus price target of $7.50, indicating a potential upside of 217.80%. Given Aclarion's stronger consensus rating and higher probable upside, analysts clearly believe Aclarion is more favorable than BioNexus Gene Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Aclarion had 1 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 2 mentions for Aclarion and 1 mentions for BioNexus Gene Lab. Aclarion's average media sentiment score of 0.42 beat BioNexus Gene Lab's score of 0.00 indicating that Aclarion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclarion	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNexus Gene Lab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BioNexus Gene Lab beats Aclarion on 9 of the 15 factors compared between the two stocks.

How does BioNexus Gene Lab compare to NewGenIvf Group?

NewGenIvf Group (NASDAQ:NIVF) and BioNexus Gene Lab (NASDAQ:BGLC) are related small-cap companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, NewGenIvf Group had 3 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 4 mentions for NewGenIvf Group and 1 mentions for BioNexus Gene Lab. NewGenIvf Group's average media sentiment score of 0.43 beat BioNexus Gene Lab's score of 0.00 indicating that NewGenIvf Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewGenIvf Group	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNexus Gene Lab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NewGenIvf Group has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, BioNexus Gene Lab has a beta of 4.17, meaning that its stock price is 317% more volatile than the broader market.

NewGenIvf Group has higher earnings, but lower revenue than BioNexus Gene Lab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewGenIvf Group	$4.73M	0.47	$9.88M	N/A	N/A
BioNexus Gene Lab	$7.43M	0.47	-$2.98M	-$1.48	N/A

66.2% of NewGenIvf Group shares are owned by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are owned by institutional investors. 31.8% of NewGenIvf Group shares are owned by company insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewGenIvf Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NewGenIvf Group has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -54.70%. NewGenIvf Group's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewGenIvf Group	N/A	N/A	N/A
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%

Summary

NewGenIvf Group beats BioNexus Gene Lab on 9 of the 11 factors compared between the two stocks.

Get BioNexus Gene Lab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGLC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BGLC vs. The Competition

Export

Metric	BioNexus Gene Lab	Trading Companies & Distributors Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$3.19M	$9.56B	$10.66B	$12.68B
Dividend Yield	N/A	3.44%	120.66%	10.03%
P/E Ratio	-0.97	28.03	27.77	25.13
Price / Sales	0.47	22.94	430.26	93.66
Price / Cash	N/A	47.70	24.04	34.82
Price / Book	0.40	3.77	4.84	6.21
Net Income	-$2.98M	$364.48M	$610.20M	$347.49M
7 Day Performance	4.38%	-0.18%	0.83%	0.89%
1 Month Performance	-29.56%	0.71%	-1.27%	-3.60%
1 Year Performance	-77.90%	9.65%	13.63%	20.46%

BioNexus Gene Lab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BGLC BioNexus Gene Lab	0.5479 of 5 stars	$1.43 +8.3%	N/A	-79.6%	$3.19M	$7.43M	N/A	30	Gap Down High Trading Volume
BMGL Basel Medical Group	N/A	$5.84 -8.3%	N/A	-76.8%	$9.97M	$8.90M	N/A	36	Gap Down
MGRX Mangoceuticals	1.3799 of 5 stars	$0.55 -0.6%	N/A	-67.4%	$9.55M	$460K	N/A	3
BRTX Biorestorative Therapies	0.8478 of 5 stars	$0.25 -7.3%	N/A	-85.5%	$6.79M	$360K	N/A	7	Positive News High Trading Volume
ACON Aclarion	3.6522 of 5 stars	$2.02 -5.2%	$7.50 +271.3%	-67.8%	$5.24M	$80K	N/A	7	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BGLC) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNexus Gene Lab (BGLC) Competitors

BGLC vs. BMGL, MGRX, BRTX, ACON, and NIVF

How does BioNexus Gene Lab compare to Basel Medical Group?

Summary

How does BioNexus Gene Lab compare to Mangoceuticals?

Summary

How does BioNexus Gene Lab compare to Biorestorative Therapies?

Summary

How does BioNexus Gene Lab compare to Aclarion?

Summary

How does BioNexus Gene Lab compare to NewGenIvf Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGLC vs. The Competition

BioNexus Gene Lab Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioNexus Gene Lab (BGLC) Competitors

BGLC vs. BMGL, MGRX, BRTX, ACON, and NIVF

How does BioNexus Gene Lab compare to Basel Medical Group?

Which has higher earnings & valuation, BMGL or BGLC?

Is BMGL or BGLC more profitable?

Which has more risk & volatility, BMGL or BGLC?

Does the media refer more to BMGL or BGLC?

Do analysts rate BMGL or BGLC?

Do insiders & institutionals hold more shares of BMGL or BGLC?

Summary

How does BioNexus Gene Lab compare to Mangoceuticals?

Which has better valuation and earnings, BGLC or MGRX?

Is BGLC or MGRX more profitable?

Which has more risk and volatility, BGLC or MGRX?

Do analysts prefer BGLC or MGRX?

Do insiders & institutionals have more ownership in BGLC or MGRX?

Does the media favor BGLC or MGRX?

Summary

How does BioNexus Gene Lab compare to Biorestorative Therapies?

Do analysts prefer BRTX or BGLC?

Does the media prefer BRTX or BGLC?

Do institutionals & insiders hold more shares of BRTX or BGLC?

Which has more risk & volatility, BRTX or BGLC?

Is BRTX or BGLC more profitable?

Which has better earnings and valuation, BRTX or BGLC?

Summary

How does BioNexus Gene Lab compare to Aclarion?

Which has higher valuation and earnings, ACON or BGLC?

Which has more risk & volatility, ACON or BGLC?

Do insiders and institutionals believe in ACON or BGLC?

Is ACON or BGLC more profitable?

Do analysts recommend ACON or BGLC?

Does the media prefer ACON or BGLC?

Summary

How does BioNexus Gene Lab compare to NewGenIvf Group?

Does the media prefer NIVF or BGLC?

Which has more risk and volatility, NIVF or BGLC?

Which has stronger valuation and earnings, NIVF or BGLC?

Do insiders & institutionals hold more shares of NIVF or BGLC?

Do analysts recommend NIVF or BGLC?

Is NIVF or BGLC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGLC vs. The Competition

BioNexus Gene Lab Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools